Latest news with #BostonGene
Business Wire
3 days ago
- Business
- Business Wire
BostonGene's Multiomic AI Platform Uncovers Therapeutic Targets in Invasive Lobular Carcinoma, Wins GRASP Advocate Choice Award at ASCO 2025
BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster, titled ' Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes,' was presented by Jason Mouabbi, MD, of The University of Texas MD Anderson Cancer Center, on June 2, 2025. "It also highlights the role of multiomic data in informing trial design, optimizing patient selection, and accelerating the development of precision oncology therapeutics.' In collaboration with MD Anderson, BostonGene applied its proprietary multiomic AI platform to profiles of over 600 patients, uncovering distinct histologic and molecular features of invasive lobular carcinoma (ILC)—a breast cancer subtype for which treatment decisions are often inferred from other subtypes. The study revealed previously under-characterized macroscale genomic alterations and biologic mechanisms, highlighting opportunities for precision-targeted therapies and novel drug development strategies tailored to ILC. These insights demonstrate BostonGene's unique capabilities to uncover disease-specific targets and enable data-driven decisions in clinical development. The GRASP (Guiding Researchers and Advocates to Scientific Partnerships) Advocate Choice Award recognizes research that is both scientifically meaningful and impactful to the patient community, as determined by cancer advocates. GRASP is a nonprofit, patient-led initiative that brings together researchers, clinicians and patients to foster scientific collaboration and accelerate innovation in cancer care. The 2025 GRASP event is held in conjunction with the ASCO Annual Meeting on June 11–12. 'We're incredibly proud to be recognized by the GRASP advocate community, which underscores the strength of our collaboration with MD Anderson and the real-world impact of BostonGene's AI-powered analytics,' said Nathan Fowler, MD, Chief Medical Officer at BostonGene. 'This study illustrates how our platform can uncover clinically actionable genomic insights and help reshape treatment paradigms for historically underserved cancer subtypes like ILC. It also highlights the role of multiomic data in informing trial design, optimizing patient selection, and accelerating the development of precision oncology therapeutics.' About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit
Business Wire
27-05-2025
- Business
- Business Wire
BostonGene to Showcase its Multimodal AI Platform Advancing Drug Development at the 2025 ASCO
WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that six abstracts have been accepted at the 2025 ASCO Annual Meeting (ASCO), scheduled to take place May 31 – June 3, 2025, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth #15147. BostonGene will showcase the impact of its validated, multimodal AI platform, which combines deep molecular profiling, immune system characterization and advanced analytics to accelerate and de-risk oncology drug development. Share BostonGene will showcase the impact of its validated, multimodal AI platform, which combines deep molecular profiling, immune system characterization and advanced analytics to accelerate and de-risk oncology drug development. Across six accepted studies—conducted independently and in collaboration with leading academic institutions—BostonGene will demonstrate how its platform uncovers novel biomarkers, refines patient stratification and predicts therapeutic response across a range of tumor types. Presentations will highlight advancements in transcriptomic analysis, immune microenvironment profiling, histomolecular subtyping and blood-based predictors—key tools for improving clinical trial design and driving precision treatment strategies. Details about the abstracts selected for presentation can be found below: Abstract number: 11536 Title: Molecular subtyping and insights into sarcoma biology and prognosis Date & time: May 31 | 9:00 AM - 12:00 PM Presenter: Nikita Kotlov, BostonGene In this study, BostonGene's multiomic Tumor Portrait TM test was used to identify distinct molecular patterns in various sarcoma subtypes that correlated with survival outcomes. These findings demonstrate the potential clinical impact of advanced analytics paired with molecular sequencing in diverse diseases such as sarcoma. Abstract number: 1049 Title: Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes Date & time: June 2 | 9:00 AM - 12:00 PM Presenter: Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center In collaboration with MD Anderson, BostonGene used its advanced analytic platform to identify unique histologic and molecular findings in invasive lobular carcinoma (ILC), a subtype of breast cancer for which treatment options are often inferred. Profiling of over 600 patients resulted in the discovery of biologic mechanisms and alterations that could direct future therapeutic and drug development strategies. Research done in collaboration with MD Anderson Cancer Center Abstract number: 11561 Title: Detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing Date & time: May 31 | 9:00 AM - 12:00 PM Presenter: Lev Bedniagin, MD, BostonGene Leveraging BostonGene's extensive internal cohort and advanced sequencing technologies, this study conducted transcriptome analysis of Liposarcoma (LPS) samples, revealing novel hotspots of gene fusions in LPS patients. These discoveries can be used to improve diagnostic accuracy and the development of novel therapeutics in LPS and similar diseases. Abstract number: 4198 Title: Uncovering the Tumor Microenvironment (TME): Exploring survival and immunotherapy (IO) response in Cancer of Unknown Primary (CUP) Date & time: May 31 | 9:00 AM - 12:00 PM Presenter: Joelle Allam, MD, The Texas University MD Anderson Cancer Center In this study, BostonGene utilized its Tumor Portrait TM test to characterize Cancer of Unknown Primary (CUP). The analysis revealed correlations of clinical factors, the tumor microenvironment and immunotherapy response with survival outcomes, offering new insights into this challenging and poorly defined cancer. Abstract number: 2634 Title: Tertiary lymphoid structures and their association with immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer Date & time: June 2 | 1:30 PM - 4:30 PM Presenter: Lev Bedniagin, MD, BostonGene Leveraging BostonGene's AI-driven Kassandra deconvolution algorithm to analyze transcriptomic data from patients with non-small cell lung cancer, this study identified unique tertiary lymphoid structures within the tumor microenvironment that may serve as predictive and prognostic biomarkers, enhancing the efficacy of immune checkpoint inhibitor therapy. This study demonstrated the clinical utility of the BostonGene Tumor Portrait TM test in guiding treatment selection for castrate-resistant prostate cancer based on tumor microenvironment-related gene signatures. These findings underscore the importance of precision medicine in managing cancer subtypes that are resistant to traditional interventions. For more information, please visit the 2025 ASCO Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings. About BostonGene Corporation BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit
Yahoo
24-03-2025
- Health
- Yahoo
BostonGene to Participate in the 114th Annual Meeting of the United States and Canadian Academy of Pathology
Showcasing AI-Powered Molecular and Immune Profiling Innovations to Advance Precision Medicine WALTHAM, Mass., March 24, 2025--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced that two abstracts have been accepted for poster presentation at the United States and Canadian Academy of Pathology (USCAP) 114th Annual Meeting. The event, held from March 22-27 at the Boston Convention and Exhibition Center in Boston, MA, is the premier gathering of pathology and laboratory medicine professionals, showcasing cutting-edge research, diagnostic advancements and emerging technologies to advance patient care and precision medicine. Details of the poster presentations are below: Title: Profiling the Intratumor Microbiome in Prostate Cancer (PC) Reveals Consistent Signatures Across Different Metastatic Sites and Correlates with the Tumor Microenvironment (TME)Abstract: 147Time and Location: Monday, March 24 | 1:00 PM - 4:30 PMPresenter: Eda Nur Kozan, MD, Weill Cornell Medicine A recent pilot study uncovered associations between bacterial profiles, the tumor microenvironment (TME), and histology in metastatic castration-resistance prostate cancer (mCRPC). Using BostonGene's machine learning-based tools, RNA sequencing data were analyzed to characterize each sample's microbiota and TME. Distinct bacterial patterns were present across prostate cancer subtypes and TME classifications, with strong correlations observed among the microbiomes of metastatic sites. Research done in collaboration with Weill Cornell Medicine Title: Reconstruction of the Glioblastoma (GBM) Tumor Immune Microenvironment (TIME) Reveals Unique Subtypes with Potential Prognostic SignificanceAbstract: 248Time and Location: Tuesday, March 25 | 9:30 AM - 12:30 PMPresenter: Eda Nur Kozan, MD, Weill Cornell Medicine This collaborative study identified novel GBM TIME subtypes associated with prognosis. Unsupervised clustering was applied to transcriptomic data from a meta-cohort of 867 publicly available samples and 30 BostonGene Tumor PortraitTM test samples to define five TIME subtypes linked with overall survival. This study illustrates the power of molecular profiling for identifying prognostic biomarkers in GBM. Research done in collaboration with Weill Cornell Medicine For more information or to schedule a meeting with BostonGene during the event, please contact Hannah Oman at events@ About BostonGene Corporation BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit View source version on Contacts Media: Erin Keleher+
Yahoo
28-01-2025
- Business
- Yahoo
BostonGene to Participate in Friends of Cancer Research Meeting
Joe Lennerz, MD, PhD, Chief Scientific Officer to Speak on Digital Pathology and AI in Diagnostics WALTHAM, Mass., January 28, 2025--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in the Friends of Cancer Research (Friends) meeting, Advancing the Future of Diagnostics and Regulatory Innovations. The event, which aims to drive innovation in diagnostics and regulatory policy, will be held on February 4 at the Ritz Carlton in Washington, DC. The meeting will focus on advancing diagnostics and regulatory policy, with sessions addressing evidence generation for cutting-edge technologies like digital pathology and AI, strategies for developing tests for rare biomarkers and future regulatory considerations. New findings from the Digital PATH Project will be presented, which assessed variability in digital pathology platforms using a shared dataset. Key thought leaders will discuss how these innovations can drive precision medicine and improve patient outcomes. BostonGene's Chief Scientific Officer, Joe Lennerz, MD, PhD, will participate in the panel session, "Evaluating Digital Pathology and AI in Diagnostics," where he will share insights on the importance of high-quality data, the importance of ground truth and integrating new diagnostics entities and technologies into patient care. Date: Tuesday, February 4 Time: 10:30 AM – 11:30 AM ET To schedule a meeting during the event, contact Allie Lewan at For more event details, visit the Friends of Cancer Research website. About BostonGene Corporation BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit View source version on Contacts Media: BostonGene Erin Keleher+ Sign in to access your portfolio
